Cardinal Health 10-Q 2026-03-31
CAH · CIK 721371 · Form 10-Q · Period ended March 31, 2026 · Filed April 30, 2026
8 sections, 238K characters. Original on sec.gov · ·
Cover and table of contents
| Table of Contents |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
| ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2026
or
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ................ to ......................
Commission File Number: 1-11373
Cardinal Health, Inc.
(Exact name of registrant as specified in its charter)
| Ohio | 31-0958666 | |||||||||||||||||||
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) | |||||||||||||||||||
| 7000 Cardinal Place | , | Dublin | , | Ohio | 43017 | |||||||||||||||
| (Address of principal executive offices) | (Zip Code) |
(614) 757-5000
(Registrant’s telephone number, including area code)
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common shares (without par value) | CAH | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☑ | Accelerated filer | ☐ | ||||||||||||||
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ | ||||||||||||||
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ
The number of the registrant’s common shares, without par value, outstanding as of April 24, 2026, was the following: 234,205,855.
| Cardinal Health Q3 Fiscal 2026 Form 10-Q |
Table of Contents
About Cardinal Health
Cardinal Health, Inc., an Ohio corporation formed in 1979, is a global healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. We provide pharmaceuticals and medical products and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists, and manufacturers for integrated care coordination.
We report our financial results in two reportable segments: Pharmaceutical and Specialty Solutions ("Pharma") segment and Global Medical Products and Distribution ("GMPD") segment. All remaining operating segments that are not significant enough to require separate reportable segment disclosures are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight® Logistics. As used in this report, “we,” “our,” “us,” and similar pronouns refer to Cardinal Health, Inc. and its majority-owned and consolidated subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2026 and fiscal 2025 and to FY26 and FY25 are to the fiscal years ending or ended June 30, 2026 and June 30, 2025, respectively.
Forward-Looking Statements
This Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates, and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A"), but there are others in this Form 10-Q, which may be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “will,” “should,” “could,” “would,” “project,” “continue,” “likely,” and similar expressions, and include statements reflecting future results or guidance, statements of outlook, and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected, or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (“2025 Form 10-K”), our Form 10-Q for the quarters ended September 30, 2025 and December 31, 2025, and other SEC filings made since June 30, 2025. Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.
Non-GAAP Financial Measures
In the "Overview of Consolidated Results" section of MD&A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the “Explanation and Reconciliation of Non-GAAP Financial Measures” section following MD&A in this Form 10-Q.
| 1 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
| MD&A | Overview |
Management's Discussion and Analysis of Financial Condition and Results of Operations
The discussion and analysis presented below is concerned with material changes in financial condition and results of operations, including amounts and certainty of cash flows from operations and from outside sources, between the periods specified in our condensed consolidated balance sheets at March 31, 2026 and June 30, 2025, and in our condensed consolidated statements of earnings and our condensed consolidated statements of cash flows for the three and nine months ended March 31, 2026 and 2025. All comparisons presented are with respect to the prior-year period, unless stated otherwise. The discussion and analysis in this Form 10-Q should be read in conjunction with the MD&A included in our 2025 Form 10-K.
| 2 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |
| MD&A | Overview |
Overview of Consolidated Results
Revenue
Revenue for the three months ended March 31, 2026 increased 11 percent to $60.9 billion from the comparative prior-year quarter, primarily due to branded and specialty pharmaceutical sales growth from existing customers. Revenue for the nine months ended March 31, 2026 increased 17 percent to $190.6 billion from the comparative prior-year period, primarily due to branded and specialty pharmaceutical sales growth from existing and new customers.
GAAP and Non-GAAP Operating Earnings
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||||||||||||||
| (in millions) | 2026 | 2025 | Change | 2026 | 2025 | Change | |||||||||||||||||||||||||||||
| GAAP operating earnings | $ | 509 | $ | 730 | (30) | % | $ | 1,884 | $ | 1,847 | 2 | % | |||||||||||||||||||||||
| State opioid assessment related to prior fiscal years | — | — | (17) | — | |||||||||||||||||||||||||||||||
| Restructuring and employee severance | 25 | 28 | 66 | 61 | |||||||||||||||||||||||||||||||
| Amortization and other acquisition-related costs | 114 | 152 | 348 | 331 | |||||||||||||||||||||||||||||||
| Acquisition-related cash and share-based compensation costs | 112 | 20 | 243 | 20 | |||||||||||||||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net | 185 | (17) | 173 | (15) | |||||||||||||||||||||||||||||||
| Litigation (recoveries)/charges, net | 11 | (105) | (7) | (176) | |||||||||||||||||||||||||||||||
| Non-GAAP operating earnings | $ | 956 | $ | 807 | 18 | % | $ | 2,690 | $ | 2,067 | 30 | % |
The sum of the components and certain computations may reflect rounding adjustments.
GAAP operating earnings for the three and nine months ended March 31, 2026 decreased 30 percent to $509 million and increased 2 percent to $1.9 billion from the comparative prior-year periods, respectively. GAAP operating earnings for the three and nine months ended March 31, 2026 was unfavorably impacted by the $184 million pre-tax non-cash goodwill impairment charge related to the Navista & ION reporting unit within the Pharma segment recognized in the current quarter, the $106 million and $165 million of net recoveries in class action antitrust litigation recognized in the comparative prior-year periods, respectively, and higher cash and share-based compensation costs resulting from the timing of acquisitions within The Specialty Alliance. See "Critical Accounting Policies and Sensitive Accounting Estimates" section of this MD&A and Note 4 of the "Notes to the Condensed Consolidated Financial Statements" for further information on the goodwill impairment.
Non-GAAP operating earnings for the three and nine months ended March 31, 2026 increased 18 percent to $956 million and 30 percent to $2.7 billion from the comparative prior-year periods, respectively. GAAP and non-GAAP operating earnings for the three and nine months ended March 31, 2026 were favorably impacted by increased contribution from branded and specialty pharmaceutical products, the impact of the acquisitions of management services organization ("MSO") platforms and Advanced Diabetes Supply Group ("ADS"), and the performance of our generics program.
| 3 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |
| MD&A | Overview |
GAAP and Non-GAAP Diluted EPS
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||||||||||||||
| ($ per share) | 2026 (2) | 2025 (2) | Change | 2026 (2) | 2025 (2) | Change | |||||||||||||||||||||||||||||
| GAAP diluted EPS (1) | $ | 1.69 | $ | 2.10 | (20) | % | $ | 5.54 | $ | 5.44 | 2 | % | |||||||||||||||||||||||
| State opioid assessment related to prior fiscal years | — | — | (0.05) | — | |||||||||||||||||||||||||||||||
| Restructuring and employee severance | 0.08 | 0.09 | 0.21 | 0.19 |
Showing the first 8K of 74K characters. Open the full section
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the quantitative and qualitative market risk disclosures included in the 2025 Form 10-K since the end of fiscal 2025 through March 31, 2026.
Item 4. Controls and Procedures
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of March 31, 2026. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of March 31, 2026, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Modification of Certain Software Systems
The Pharma segment is in the process of modifying certain finance and operating information systems related to ongoing supply chain optimization initiatives. If these systems and processes are not effectively implemented or fail to operate as intended, it could adversely affect our internal control over financial reporting.
| 18 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |
| Other |
Legal Proceedings
The legal proceedings described in Note 6 of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.
Item 1A. Risk Factors
Risk Factors
You should carefully consider the information in this Form 10-Q and the risk factors discussed in "Risk Factors" and other risks discussed in the 2025 Form 10-K, our Form 10-Q for the quarters ended September 30, 2025 and December 31, 2025, and our other filings with the SEC since June 30, 2025. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.
Changes or uncertainty in U.S. or international trade policies and exposure to economic, political and currency, and other risks could disrupt our global operations or negatively impact our financial results.
We conduct our operations in various regions of the world outside of the United States, including Europe, Asia, and Latin America. Global developments can affect our business in many ways. Our global operations are affected by local economic environments, including inflation, recession, and competition. Additionally, divergent or unfamiliar regulatory systems and labor markets can increase the risks and burdens of operating in numerous countries.
In February 2025, the United States imposed tariffs under the International Emergency Economic Powers Act (IEEPA) on certain goods, materials and products imported into the United States from countries where we do business. In February 2026, the U.S. Supreme Court ruled that the IEEPA tariffs were unlawful but did not establish a mechanism for issuing refunds and uncertainty remains concerning the timing, scope and administrative process to receive refunds for IEEPA tariffs paid. In April 2026, Customs and Border Protection (CBP) launched its program to administer Phase 1 refund requests; however, substantially all of our IEEPA tariffs will fall under Phase 2 or later phases. CBP has not communicated a date on which the refund process for such Phase 2 or later phases will be established or available.
As of the third quarter of fiscal year 2026, we have paid approximately $200 million in IEEPA tariffs, primarily related to products that we source, manufacture or distribute in our GMPD segment. In the event that we receive refunds of IEEPA tariffs from the government, we expect to return to those customers the portion of those refunds that reflect the estimated increased prices related to IEEPA tariffs.
We have not recognized any financial impact related to potential tariff refunds or payments to our customers as of March 31, 2026. The ultimate resolution of this matter could positively impact our results of operations in future periods, including GMPD segment profit and consolidated operating income; however the timing and process for receipt of these refunds remains uncertain.
Following the Supreme Court IEEPA ruling, the U.S. government replaced IEEPA tariffs with tariffs imposed under Section 122 of the Trade Act of 1974. We continue to evaluate the impact of these and other tariffs, including tariffs imposed under Sections 301 and 232 of the Trade Act of 1974.
We have taken actions to reduce the impact of IEEPA and other tariffs on our financial results, including through cost optimization initiatives and by increasing prices on impacted products to customers; however, these measures have not fully offset the negative impact. Tariffs imposed or threatened to be imposed on goods, materials, and products from countries where we do business, and any retaliatory actions taken by such countries could result in us incurring substantial additional costs to source materials, directly and indirectly, from affected countries, and require us to raise prices on certain products and seek alternative sources of supply. If our competitors do not increase prices, or increase prices to a lesser extent than we do, or are able to offset the impact of tariffs through other actions, our competitive and financial position may be adversely affected. Additionally, if we are not able to find adequate alternate sources of supply, we may experience supply shortages or disruptions. Additionally, in certain circumstances, including in our Other operating segment, we may not receive increased reimbursement commensurate with the increase in costs, which may negatively impact our results of operations.
In addition, we conduct our business in U.S. dollars and various functional currencies of our foreign subsidiaries. Changes in foreign currency exchange rates could adversely affect our financial results, which are reported in U.S. dollars. We may not be able to hedge to protect us against these exposures, and any hedges may not successfully mitigate these exposures.
We are also subject to government import and export controls and regulations, including the requirement that we make a determination as to the country of origin of products that we source or manufacture outside the United States. From time to time, Customs and Border protection agencies, whether in the U.S. or other jurisdictions, have challenged these determinations. These and other actions by border protection have resulted in products being detained or delayed and supply disruptions and could result in the imposition of fines and penalties. In addition, the Uyghur Forced Labor Prevention Act, which went into effect in June 2022, prohibits the importation of any goods grown, produced, manufactured, or mined, wholly or in part, in the Xinjiang Uyghur Autonomous Region of China unless importers can provide clear and convincing evidence that goods were not made using forced labor. We have experienced supply constraints as a result
| 19 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |
| Other |
of these and similar regulations, and it is possible that our business or results of operations could be further negatively impacted by future determinations and disruptions.
Our business is affected by events outside of our control including public health crises, extreme weather-related events and natural disasters, geopolitical, and other catastrophic events.
We have experienced and expect to continue to experience weather-related impacts to the business, primarily driven by risks to certain physical components of our operations and risks related to the transition to a lower-carbon economy. For example, our properties have experienced physical damage resulting from adverse or extreme weather resulting in increased costs for repairs and may cause disruptions in operations. Additional risks associated with extreme weather may cause social and human effects such as shifts in populations, increased costs for critical services such as transportation, and other adverse effects. These factors may negatively impact cost or availability of certain products, commodities, or energy, and could impair our ability to secure goods and services required for the operation of our business at quantities and levels we require.
Environmental and other climate-related laws and regulations may impose costs, including increased spend associated with carbon pricing mechanisms, data gathering and reporting, third-party attestations, capital expenditures to implement lower greenhouse gas emissions technology, and other measures to reduce emissions. We cannot predict the potential impact on our competitive position, results of operations, or financial condition. A shift in customer or consumer preference towards low-carbon products and services may also place us at a competitive disadvantage if we fail to effectively adjust for these shifts. Our supply chain is subject to these same physical and transitional risks.
Events outside of our control also have, and will continue to, adversely impact our operations and financial results. These events include those related to public health crises, including epidemics or pandemics; geopolitical events or tensions, including civil unrest, trade sanctions, tariffs and other trade restrictions, armed conflicts, or terrorism; or unstable international governments and legal systems. Among other potential affects, these events may have a disruptive and unpredictable impact on our operations and those of our suppliers and vendors, or customers, hinder manufacturing and transportation, result in significant excess costs, lead to shifts in customer demand, or have a negative impact on capital markets. For example, the recent conflict in Iran has resulted increased fuel prices which may lead to increased costs for products that we source, manufacture or distribute and may also cause supply chain or manufacturing disruptions, impacting our ability to meet demand. Such events are inherently unpredictable, and our responses may involve the implementation of measures which may not be as successful as intended in mitigating adverse impacts.
Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
| Period | Total Number of Shares Purchased (1,2) | Average Price Paid per Share (2) | Total Number of Shares Purchased as Part of Publicly Announced Programs (2,3) | Approximate Dollar Value of Shares That May Yet be Purchased Under the Program (3) (in millions) | |||||||||||||||||||
| January 2026 | 22 | $ | 216.55 | — | $ | 1,993 | |||||||||||||||||
| February 2026 | 8 | 237.13 | — | 1,993 | |||||||||||||||||||
| March 2026 | 928,446 | 215.42 | 928,419 | 1,793 | |||||||||||||||||||
| Total | 928,476 | $ | 215.43 | 928,419 | $ | 1,793 |
(1)Reflects 22, 8, and 27 common shares purchased in January, February, and March 2026, respectively, through a rabbi trust as investments of participants in our Deferred Compensation Plan.
(2)On March 12, 2026, we entered into an ASR program to purchase common shares for an aggregate purchase price of $250 million and received an initial delivery of 0.9 million common shares using a reference price of $215.42. The ASR program concluded on April 20, 2026 at a volume weighted average price per common share of $209.55 resulting in a final delivery of 0.3 million common shares. See Note 10 of the "Notes to Condensed Consolidated Financial Statements" for additional information.
(3)On June 7, 2023, our Board of Directors approved a $3.5 billion share repurchase program, which will expire on December 31, 2027. As of March 31, 2026, we had $1.8 billion authorized for share repurchases remaining under this program.
| 20 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |
Item 5. Other Information
| Other |
Other Information
Rule 10b5-1 Plan Adoptions and Modifications
During the three months ended March 31, 2026, no director or officer adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule10b5-1 trading arrangement" as each term is defined in Item 408 of Regulation S-K under the Exchange Act.
| 21 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |
Item 1. Financial Statements
| Financial Statements |
Condensed Consolidated Statements of Earnings
(Unaudited)
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in millions, except per common share amounts) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Revenue | $ | 60,940 | $ | 54,878 | $ | 190,576 | $ | 162,419 | |||||||||||||||
| Cost of products sold | 58,442 | 52,755 | 183,362 | 156,453 | |||||||||||||||||||
| Gross margin | 2,498 | 2,123 | 7,214 | 5,966 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Distribution, selling, general and administrative expenses | 1,542 | 1,315 | 4,507 | 3,898 | |||||||||||||||||||
| Restructuring and employee severance | 25 | 28 | 66 | 61 | |||||||||||||||||||
| Amortization and other acquisition-related costs | 114 | 152 | 348 | 331 | |||||||||||||||||||
| Acquisition-related cash and share-based compensation costs | 112 | 20 | 243 | 20 | |||||||||||||||||||
| Impairments and (gain)/loss on disposal of assets, net | 185 | (17) | 173 | (15) | |||||||||||||||||||
| Litigation (recoveries)/charges, net | 11 | (105) | (7) | (176) | |||||||||||||||||||
| Operating earnings | 509 | 730 | 1,884 | 1,847 | |||||||||||||||||||
| Other (income)/expense, net | 16 | (9) | (5) | (11) | |||||||||||||||||||
| Interest expense, net | 101 | 74 | 269 | 141 | |||||||||||||||||||
| Earnings before income taxes | 392 | 665 | 1,620 | 1,717 | |||||||||||||||||||
| Provision for income taxes | 12 | 157 | 315 | 391 | |||||||||||||||||||
| Net earnings | 380 | 508 | 1,305 | 1,326 | |||||||||||||||||||
| Less: Net (earnings)/loss attributable to noncontrolling interests | 19 | (2) | 11 | (4) | |||||||||||||||||||
| Net earnings attributable to Cardinal Health, Inc. | $ | 399 | $ | 506 | $ | 1,316 | $ | 1,322 | |||||||||||||||
| Earnings per common share attributable to Cardinal Health, Inc.: | |||||||||||||||||||||||
| Basic | $ | 1.69 | $ | 2.11 | $ | 5.56 | $ | 5.47 | |||||||||||||||
| Diluted | 1.69 | 2.10 | 5.54 | 5.44 | |||||||||||||||||||
| Weighted-average number of common shares outstanding: | |||||||||||||||||||||||
| Basic | 235 | 240 | 237 | 242 | |||||||||||||||||||
| Diluted | 236 | 241 | 238 | 243 | |||||||||||||||||||
| Cash dividends declared per common share | $ | 0.5107 | $ | 0.5056 | $ | 1.5321 | $ | 1.5168 |
See notes to condensed consolidated financial statements.
| 22 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |
| Financial Statements |
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in millions) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net earnings | $ | 380 | $ | 508 | $ | 1,305 | $ | 1,326 | |||||||||||||||
| Other comprehensive income/(loss): | |||||||||||||||||||||||
| Foreign currency translation adjustments and other | (2) | (2) | 3 | (13) | |||||||||||||||||||
| Net unrealized gain/(loss) on derivative instruments, net of tax | (6) | 6 | (9) | 4 | |||||||||||||||||||
| Total other comprehensive income/(loss), net of tax | (8) | 4 | (6) | (9) | |||||||||||||||||||
| Total comprehensive income | 372 | 512 | 1,299 | 1,317 | |||||||||||||||||||
| Less: comprehensive (income)/loss attributable to noncontrolling interests | 19 | (2) | 11 | (4) | |||||||||||||||||||
| Total comprehensive income attributable to Cardinal Health, Inc. | $ | 391 | $ | 510 | $ | 1,310 | $ | 1,313 |
See notes to condensed consolidated financial statements.
| 23 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |
| Financial Statements |
Condensed Consolidated Balance Sheets
| (in millions) | **Marc |
Showing the first 8K of 132K characters. Open the full section
Item 6. Exhibits
| Exhibits |
Exhibits
Cardinal Health Website
Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations, and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when we post news releases, SEC filings, and certain other information on its website.
| 44 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |
| Form 10-Q Cross Reference Index |
Form 10-Q Cross Reference Index
| Item Number | Page | |||||||
| Part I. Financial Information | ||||||||
| Item 1 | Financial Statements | 22 | ||||||
| Item 2 | Management's Discussion and Analysis of Financial Condition and Results of Operations | 2 | ||||||
| Item 3 | Quantitative and Qualitative Disclosures about Market Risk | 18 | ||||||
| Item 4 | Controls and Procedures | 18 | ||||||
| Part II. Other Information | ||||||||
| Item 1 | Legal Proceedings | 19 | ||||||
| Item 1A | Risk Factors | 19 | ||||||
| Item 2 | Unregistered Sales of Equity Securities and Use of Proceeds | 20 | ||||||
| Item 3 | Defaults Upon Senior Securities | N/A | ||||||
| Item 4 | Mine Safety Disclosures | N/A | ||||||
| Item 5 | Other Information | 21 | ||||||
| Item 6 | Exhibits | 44 | ||||||
| Signatures | 46 |
| N/A | Not applicable |
| 45 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |
| Additional Information |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Cardinal Health, Inc. | ||||||||
| Date: | April 30, 2026 | /s/ JASON M. HOLLAR | ||||||
| Jason M. Hollar | ||||||||
| Chief Executive Officer | ||||||||
| Date: | April 30, 2026 | /s/ AARON E. ALT | ||||||
| Aaron E. Alt | ||||||||
| Chief Financial Officer |
| 46 | Cardinal Health | Q3 Fiscal 2026 Form 10-Q |